CRISPR Therapeutics AG
NASDAQ Global MarketTotal Valuation
CRISPR Therapeutics AG carries a market capitalization of 4.98B, placing it among publicly traded companies globally. Its enterprise value stands at 3.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.98B |
| Enterprise Value | 3.69B |
Share Statistics
CRISPR Therapeutics AG currently has 96.66M shares outstanding.
| Shares Outstanding | 96.66M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 469.96, and the price-to-book ratio stands at 3.02.
| PE Ratio | N/A |
| PS Ratio | 469.96 |
| PB Ratio | 3.02 |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | -14.05 |
| P/OCF Ratio | -13.99 |
Enterprise Valuation
| EV / Sales | 335.57 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
CRISPR Therapeutics AG maintains a current ratio of 17.85, meaning it holds 17.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.85 |
| Quick Ratio | 17.79 |
| Debt / Equity | 44.87 |
| Debt / EBITDA | -1.52 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -26.09 |
| Return on Assets (ROA) | -19.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 3.03M |
| Effective Tax Rate | N/A |
Stock Price Statistics
CRISPR Therapeutics AG's stock has declined approximately -28.26511% over the past 52 weeks. The 50-day moving average sits at 55.01, while the 200-day moving average is 53.14.
| Beta (5Y) | N/A |
| 52-Week Price Change | -28.26511% |
| 50-Day Moving Average | 55.01 |
| 200-Day Moving Average | 53.14 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, CRISPR Therapeutics AG generated 11.00M in revenue and converted that into -451.14M in net income, yielding earnings per share of -4.76. EBITDA reached -515.65M, while operating income came in at -534.34M.
| Revenue | 11.00M |
| Gross Profit | -186.04M |
| Operating Income | -534.34M |
| Pretax Income | -448.11M |
| Net Income | -451.14M |
| EBITDA | -515.65M |
| EBIT | -534.34M |
| Earnings Per Share (EPS) | -4.76 |
Balance Sheet
CRISPR Therapeutics AG holds 2.36B in cash and equivalents against 783.75M in total debt, resulting in a net debt position of 294.86M. Total book value stands at 1.75B, with working capital of 2.24B providing operational flexibility.
| Cash & Cash Equivalents | 2.36B |
| Total Debt | 783.75M |
| Net Debt | 294.86M |
| Equity (Book Value) | 1.75B |
| Book Value Per Share | 18.07 |
| Working Capital | 2.24B |
Cash Flow
CRISPR Therapeutics AG produced -369.58M in operating cash flow over the past twelve months. After subtracting -1.74M in capital expenditures, free cash flow totaled -371.32M - equivalent to -3.92 per share.
| Operating Cash Flow | -369.58M |
| Capital Expenditures | -1.74M |
| Free Cash Flow | -371.32M |
| FCF Per Share | -3.92 |
Margins
CRISPR Therapeutics AG operates with a gross margin of -1,691.26, reflecting its pricing power and cost economics. The operating margin of -4,857.64 and net profit margin of -4,101.26 provide insight into operational efficiency.
| Gross Margin | -1,691.26 |
| Operating Margin | -4,857.64 |
| Pretax Margin | -4,073.70 |
| Profit Margin | -4,101.26 |
| EBITDA Margin | -4,687.70 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -19.20 |
| FCF Yield | -7.12 |
Scores
CRISPR Therapeutics AG posts an Altman Z-Score of 2.71, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.71 |